Hernan Salazar, DO
Internal Medicine · San Antonio, TXNPI 1538220892
Payments from drug & device makers
Across 478 payments — averaging $38,737 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$6.7M
- Innocoll Pharmaceuticals Limited$3.2M
- Heron Therapeutics, Inc.$2.1M
- Vertex$2M
- Dexcom, Inc.$1.3M
- Eli Lilly$974K
- plus $2.2M from 13 others
Across 6 payments — averaging $472.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 86 | $6,720,315 |
| Innocoll Pharmaceuticals Limited | 25 | $3,161,672 |
| Heron Therapeutics, Inc. | 27 | $2,119,911 |
| Vertex | 7 | $2,034,884 |
| Dexcom, Inc. | 50 | $1,313,407 |
| Eli Lilly | 47 | $973,679 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $839,874 |
| Siemens Medical Solutions USA, Inc. | 7 | $291,325 |
| Endo Pharmaceuticals Inc. | 43 | $255,829 |
| Boehringer Ingelheim International GmbH | 39 | $191,565 |
| Astrazeneca UK Limited | 4 | $151,587 |
| AbbVie | 28 | $131,944 |
| Pfizer | 14 | $84,588 |
| Alnylam Pharmaceuticals Inc. | 47 | $75,691 |
| Biontech SE | 7 | $60,890 |
| Novartis | 14 | $50,863 |
| Amgen | 2 | $24,259 |
| Genentech, Inc. | 1 | $23,491 |
| Novo Nordisk AS | 5 | $10,557 |
How this compares
$18,516,330 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in San Antonio
- Robert BassSan Antonio$25.6M
- Dennis RuffSan Antonio$7.5M
- Cassandra KeySan Antonio$5.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.